Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) is a global medical technology company whose news flow centers on hospital technologies, plasma collection systems and blood center products. Company communications describe a focus on improving the quality, effectiveness and efficiency of health care, so news items often highlight developments that affect these areas.
Investors following HAE news can expect regular announcements about quarterly financial results, including the availability of earnings releases and details for conference calls and webcasts with investors and analysts. These updates are typically accompanied by Form 8-K filings that furnish the related press releases and summarize results for specific fiscal quarters.
Haemonetics also issues news about its participation in healthcare investment conferences, such as presentations at the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events provide additional context for the company’s strategy and operations in the medical technology space.
A notable category of news involves corporate transactions and interventional technologies. For example, Haemonetics announced the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation percutaneous vessel closure technology. Press releases describe how Vivasure’s PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore arterial and venous closure, is intended to expand Haemonetics’ range of closure devices and its presence in the large-bore closure market.
By monitoring the Haemonetics news page, readers can track earnings communications, conference participation, regulatory and acquisition-related updates, and other material events disclosed through press releases and SEC filings. This provides a consolidated view of developments affecting HAE within the surgical and medical instrument manufacturing industry.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, the President and CEO, will present at the Jefferies Plasma Summit on March 11, 2021, at 10:45 a.m. ET. The presentation will be accessible live via webcast, with a replay available for one month. Haemonetics is focused on delivering innovative medical products and solutions, primarily in blood and plasma collection, surgical services, and hospital transfusions.
Haemonetics Corporation (NYSE: HAE) announced the availability of its third-quarter fiscal 2021 financial results, concluding on December 26, 2020. A conference call is scheduled for February 2, 2021, at 8:00 a.m. ET, to discuss the results and address investor queries. The earnings release, analytical tables, and details regarding the acquisition of Cardiva Medical, Inc. have been posted on the Investor Relations website. The company's innovative healthcare solutions aim to enhance patient care while reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) supports the FDA's new guidance on viscoelastic testing during the COVID-19 pandemic. The company is modifying labeling for its TEG® 5000 and TEG® 6s hemostasis analyzers to enhance patient care. These analyzers provide critical insights into blood clotting, addressing coagulopathy associated with COVID-19, which can lead to severe complications. Haemonetics aims to optimize blood resource utilization while ensuring that healthcare professionals have access to necessary technologies during this crisis.
Haemonetics (NYSE: HAE) has announced a definitive agreement to acquire Cardiva Medical for $475 million upfront, plus $35 million contingent on sales growth. This strategic acquisition aims to enhance Haemonetics' offerings in interventional cardiology and electrophysiology markets. The deal is expected to generate $65-$75 million in revenue in its first fiscal year but may dilute adjusted net earnings by $0.15 to $0.20 in fiscal 2022. The acquisition is projected to break even on earnings by fiscal 2023 and deliver a 10% return on invested capital by year five.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2021 financial results on February 2, 2021, at 6:00 am EDT. Following this, a conference call for investors and analysts will occur at 8:00 am EDT on the same day to discuss the results. Access to the call is available via toll-free and international numbers, with a conference ID required. A live webcast will also be available on Haemonetics' investor relations website, with a replay accessible from February 2 to February 10, 2021.
Haemonetics Corporation (NYSE:HAE) has released its financial results for the second quarter of fiscal 2021, concluding on September 26, 2020. The earnings release and results tables are accessible on its Investor Relations website, along with a scheduled conference call for investors on November 4, 2020, at 8 a.m. EST. Key financial metrics and strategic updates are expected to be discussed during this call. Investors can also view the live webcast for detailed insights into the company's performance.
Haemonetics Corporation (NYSE: HAE) announced the upcoming release of its second quarter fiscal year 2021 financial results, scheduled for November 4, 2020, at 6:00 am EDT. Following the announcement, the Company will host a conference call at 8:00 am EDT to discuss the results and address investor inquiries. The call can be accessed via a toll-free number or through a live webcast on Haemonetics' investor relations website. A replay of the webcast will be available from November 4 to November 12, 2020.
On October 2, 2020, Haemonetics Corporation (NYSE: HAE) announced FDA 510(k) clearance for its NexSys PCS® system with Persona™ technology. This innovative system customizes plasma collection based on individual donor body composition. Results from the IMPACT study showed an 8.2% increase in collected plasma volume. Persona technology optimizes collection for donors based on BMI and hematocrit.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on September 15, 2020, at 9:30 a.m. ET. The presentation will be accessible to the public via a live webcast and subsequent replay.
Haemonetics specializes in innovative hematology products aimed at enhancing patient care and reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) announced that results from its IMPACT study will be presented at the AABB Annual Meeting on October 4, 2020. The study, involving 3,443 donors and 23,137 plasma donations, tested a novel, personalized approach to plasma collection using the NexSys PCS® Plasma Collection System. The findings indicated an 8.2% increase in plasma volume collected per donation while maintaining a safe profile. This innovation addresses the growing demand for plasma-derived therapies, with the NexSys PCS device pending FDA approval.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
